Ulviprubart is under clinical development by Abcuro and currently in Phase III for Inclusion Body Myositis (IBM). According to GlobalData, Phase III drugs for Inclusion Body Myositis (IBM) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ulviprubart LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ulviprubart overview

Ulviprubart (AB-008) is under development for the treatment of inclusion body myositis (IBM), T and natural killer (NK) cell lymphomas and T-cell large granular lymphocyte (LGL) leukemia. It acts by targeting KLRG1. It is administered through subcutaneous route.

It was also under development for the treatment of primary biliary cholangitis (PBC)

Abcuro overview

Abcuro is a developer of first-in-class immunotherapies for autoimmune diseases and cancer through precise elimination or modulation of cytotoxic T and NK cells via KLRG1. Abcuro is headquartered in Newton, Massachusetts, the US.

For a complete picture of Ulviprubart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.